登录新浪财经APP 搜索【信披】查看更多考评等级 数 智通财经记者 | 孙艺真 智通财经从券商人士处获悉，近期，沪、深交易所向券商下发最新一期《发行上市审核动态》，两所均 对申报前咨询沟通有关工作要求进行解答。 据来源：东财Choice，智通财经制图 从IPO受理情况来看，近期IPO受理端整体迎来暖意。智通财经记者根据东财Choice数据统计，今年6至 7月，共有151家企业IPO获得交易所受理。其中，北交所企业IPO受理为主力，数量为97家；科创板共 有19家企业IPO获得受理，泰诺麦博在科创板第五套上市标准重启后首获受理；沪市主板、深市主板及 创业板受理数量则分别有7家、9家和19家。 "预沟通不是预审核。"深交所在此次下发的文件中明确重申，"本所只对涉及规则理解和适用问题进行 答复，不对具体项目是否符合发行条件、上市条件和信息披露要求进行实质性判断或保证。咨询人不得 将预沟通回复作为判断能否通过审核的依据，也不得将预沟通回复作为推卸责任的理由。" 上交所亦提及："申报前咨询沟通不是项目申报受理的必备程序，沟通结果与项目是否受理、是否审核 通过无关。" 也有投行人士向智通财经表示，"IPO预先审阅机制"试 ...

Group 1 - The core viewpoint of the report highlights the accelerated inclusion of anti-tumor drugs in the medical insurance directory, with significant effects from target coverage and volume expansion [2][10] - In 2024, 91 new drugs were added to the medical insurance directory, of which 29 were anti-tumor and immune modulators, accounting for 32% of the total [10][11] - The hospital sales revenue for anti-tumor and immune modulators reached 57.9 billion yuan, representing over half of the total sales for negotiated varieties [10][11] Group 2 - The report notes that the new anti-tumor drugs are predominantly focused on lung cancer, with 11 new drugs added for this indication, while no new drugs were included for liver, stomach, or esophageal cancers [4][23] - The current directory adjustments do not align with the cancer spectrum in China, where lung cancer accounts for 27.7% of cancer deaths, indicating unmet needs in other cancer types [4][23] Group 3 - High-priced therapies face dual challenges regarding medical insurance funds and efficacy value, particularly CAR-T therapies, which are priced significantly above the implicit payment threshold [5][27] - The report emphasizes the need for innovative payment ecosystems to support high-value therapies, as the current pricing and reimbursement models are unsustainable [28][27]

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Insights - The Sci-Tech Innovation Board (STAR Market) has completed six years, focusing on institutional innovation and ecological development to foster a conducive environment for scientists and high-level tech talent [1][9] - Over 60% of STAR Market companies have founding teams composed of scientists, engineers, or industry experts, with nearly 40% collaborating with universities and research institutions [1][2] Group 1: Talent and Innovation - The STAR Market features a distinct characteristic of scientist-led entrepreneurship, with over 60% of companies having founders from scientific backgrounds [2][3] - A significant number of companies are led by individuals with academic experience, including 75 companies having leaders with professor or doctoral advisor roles [3][4] - Approximately 110 STAR Market company leaders graduated from China's C9 universities, contributing to the industry's clustering advantage [4][5] Group 2: Industry Collaboration - The STAR Market companies have a high rate of collaboration with academic institutions, with over 80% engaging in partnerships for research and development [6][7] - More than 70% of companies collaborate with 985/211 universities or Chinese Academy of Sciences for R&D, and over 40% engage in joint talent cultivation [6][7] - The number of collaborative projects with universities and research institutions has exceeded 4,000 in the past three years, with over 1,100 projects achieving commercialization [7][8] Group 3: Intellectual Property and R&D - STAR Market companies have collectively generated over 120,000 invention patents, with more than 20,000 new patents filed in 2024 alone [8] - The board has implemented a flexible equity incentive system, with over 70% of companies utilizing it to attract and retain talent [9] - The total number of R&D personnel in STAR Market companies has surpassed 240,000, accounting for nearly 30% of the total workforce [9]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant growth, with a record-breaking $60.5 billion licensing agreement between 3SBio and Pfizer, marking a milestone in China's innovative drug transactions [1] - In the first half of 2025, over 50 global collaborations were established in the Chinese innovative drug sector, totaling $48.448 billion, alongside 154 new drug clinical approvals and 16 innovative drugs successfully launched [2][3] - The Hong Kong innovative drug ETF has seen a remarkable year-to-date increase of 58.95%, outperforming the Hang Seng Index and technology index [1] Industry Developments - The number of new drug clinical approvals reached 154 in June 2025, a 9% increase from the previous month, with bispecific antibodies and ADC drugs becoming the core areas of technological breakthroughs [2] - The Chinese innovative drug sector is transitioning from a "pharmaceutical giant" to a "pharmaceutical powerhouse," with the number of original innovative drugs in development now ranking first globally [2][3] - The introduction of a "commercial health insurance innovative drug directory" by the National Healthcare Security Administration is expected to create new payment channels for high-priced innovative drugs [3][4] Market Trends - The proportion of oncology pipeline transactions has decreased from 72% in 2023 to 61% in 2024, while the share of metabolic endocrine and autoimmune fields has increased to 25% [3] - The domestic innovative drug self-pay market is projected to grow from 320 billion yuan in 2024 to 1 trillion yuan by 2030, providing ample space for high-priced innovative drugs [3][4] Financial Performance - The proportion of R&D expenditure relative to revenue for innovative drug companies has decreased from 157% in 2023 to 89% currently, with some companies achieving net profit margins of 15% to 20% [5][6] - The top ten weighted stocks in the Hong Kong innovative drug selection index account for 75.85% of the index, indicating a concentration of market power among leading firms [5] Internationalization Strategies - Leading companies are shifting from "product export" to "platform export," while smaller firms are adopting the NewCo model to reduce reliance on single markets [6] - Recommendations include establishing cross-border platforms to provide comprehensive support for international expansion and fostering patient capital to better integrate financial resources with technological innovation [6]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [4] Core Insights - The innovative drug sector has seen a significant increase in institutional interest, with the total heavy positions in Biotech innovative drugs reaching 80.371 billion yuan, a quarter-on-quarter growth of 39% [7][18] - The proportion of heavy positions in Biotech innovative drugs relative to the overall market has increased to 2.39%, up by 0.49 percentage points, indicating sustained enthusiasm from institutions towards the innovative drug sector [19][25] - The heavy positions in Biotech innovative drugs account for 24.93% of the total heavy positions in the pharmaceutical industry, reflecting a rise of 5.49 percentage points [19][25] Summary by Sections Weekly Review of New Drug Market - From July 28 to August 1, 2025, the top five companies in the new drug sector by stock price increase were: Zhongsheng Pharmaceutical (29.53%), WuXi AppTec (17.72%), CSPC Pharmaceutical Group (14.60%), Maiwei Biotech (12.08%), and Haizhi Pharmaceutical (11.76%) [14][15] - The top five companies by stock price decrease were: Kintor Pharmaceutical (-19.09%), Hualing Pharmaceutical (-16.19%), Junsheng Pharmaceutical (-13.24%), Kintor Pharma (-12.70%), and Yunding New Drug (-11.29%) [14][15] Key Analysis of New Drug Industry - The report analyzed the latest heavy positions of all funds in the innovative drug sector as of June 30, 2025, focusing on A-share and Hong Kong Biotech companies [18] - The heavy positions in Biotech innovative drugs accounted for 7.05% of the total market capitalization, an increase of 0.93 percentage points [23][28] New Drug Approval and Acceptance - This week, 13 new drug or new indication applications were approved, including drugs such as Risperidone orally disintegrating film and Nivolumab injection [33][34] - Additionally, 6 new drug or new indication applications were accepted, including drugs like Eptinezumab injection and Edaravone tablets [35][36] Clinical Application Approval and Acceptance - A total of 50 new drug clinical applications were approved this week, while 44 new drug clinical applications were accepted [37]

Group 1 - Recent U.S. non-farm payroll data fell short of expectations, causing declines in European and American stock markets, leading to concerns about potential further pullbacks in the A-share market [1] - Investors have expressed frustration over the inability to profit despite market gains, indicating a disconnect between market performance and individual stock returns [1][23] - The information overload in the current market environment has made it challenging for investors to discern valuable insights, highlighting the need for improved information filtering and trading strategies [1][23] Group 2 - The "Fireline Quick Review" service has provided valuable insights, identifying several sectors that have performed well, including the Nvidia supply chain, innovative pharmaceuticals, and rare earths [2][21] - Specific examples include the Nvidia supply chain, which was highlighted on May 14, leading to significant stock price increases, with Industrial Fulian rising from around 18 yuan to a peak of 35.90 yuan [2][5] - The Hainan Free Trade Zone was noted for its readiness for operation, resulting in stock price increases for related companies like Hainan Airport and China Duty Free [5] Group 3 - The electronic fabric sector was identified early in June, with stocks like Honghe Technology doubling in value, reflecting the effectiveness of timely information [7] - The rare earth and innovative pharmaceutical sectors have also seen substantial gains, with stocks like Shenghe Resources experiencing a doubling in price [9][11] - The express delivery sector has shown strong performance, with a 20% year-on-year increase in business volume in the first five months, leading to significant stock price increases for companies like YTO Express and Yunda [13] Group 4 - The weight loss drug sector has performed strongly, with stocks like Changshan Pharmaceutical doubling in value after being identified as a potential beneficiary of inclusion in the WHO essential medicines list [16] - The civil explosives sector benefited from developments in hydropower projects in Tibet, with stocks like Yipuli and Jiangnan Chemical experiencing consecutive price increases [18] - The importance of seizing opportunities before stock prices surge is emphasized, as late entry often results in missed profits [20]

Group 1 - On August 1, Dize Pharmaceutical had a financing buy-in amount of 0.16 billion, ranking 870th in the two markets [1] - The financing repayment amount on the same day was 0.23 billion, resulting in a net sell of 6.50 million [1] - Over the last three trading days, Dize Pharmaceutical received financing buy-ins of 0.14 billion, 0.19 billion, and 0.16 billion respectively [1] Group 2 - On the same day, the securities lending saw a sell of 0.00 thousand shares, with a net buy of 0.02 thousand shares [1]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector is as follows: - Below 500,000 yuan: 153 individuals (32%) - 500,000 to 1 million yuan: 199 individuals (41%) - 1 million to 2 million yuan: 114 individuals (23%) - 2 million to 3 million yuan: 16 individuals (3%) - Above 3 million yuan: 5 individuals (1%) [5] Age Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute the majority at 47%, while those over 50 account for 23%. The 30-40 age group makes up 29%, and those under 30 represent 1%, with the youngest being 28 years old [1] Educational Background - The educational qualifications of company secretaries are as follows: - Associate degree: 4% - Bachelor's degree: 42% - Master's degree: 50% - Doctorate: 4% - More than half of the company secretaries hold a master's degree or higher [3] Investor Engagement - The frequency of investor engagement varies significantly among companies: - Less than 10 times: 129 companies (32%) - 10 to 100 times: 149 companies (37%) - 100 to 300 times: 79 companies (20%) - 300 to 1000 times: 42 companies (10%) - More than 1000 times: 5 companies (1%) [9] Top Investor Engagement Companies - The companies with the highest number of investor engagements are: - Sanofi Biologics: 2661 times - Bohui Innovation: 1500 times - Zexin Pharmaceutical: 1418 times - Aibo Medical: 1263 times - Kangtai Medical: 1107 times - The respective salaries of their company secretaries are 1.1449 million yuan, 1.2012 million yuan, 1.4776 million yuan, 683,300 yuan, and 378,000 yuan [10]

Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]